DNA molecule, illustration.
Our Work

Latham & Watkins Advises on BridgeBio’s Public Offering of Common Stock

March 6, 2024
Firm represents the underwriters in the offering by the commercial-stage biopharmaceutical company.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced the pricing on March 5, 2024 of an underwritten public offering of 8,620,690 shares of its common stock at a public offering price of US$29 per share, before deducting underwriting discounts and commissions. In addition, BridgeBio has granted the underwriters a 30-day option to purchase up to an additional 1,293,103 shares of its common stock on the same terms and conditions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately US$250 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering to be sold by BridgeBio.

Latham & Watkins is representing the underwriters in the offering, with a capital markets team lead by Orange County partner Shayne Kennedy and Bay Area partner Phillip Stoup, with associates Tess Bloom, Taimi Jacobson, Chelsi DeTurk, and Ryleigh Chen. Advice was also provided on regulatory matters by Washington, D.C. partner Ben Haas and Bay Area partner Betty Pang, with associates Nathan Beaton and Kiera Murphy; on IP matters by Bay Area partner Christopher Hazuka, with associates Rob Yeh and Kristina Funahashi; and on tax matters by Bay Area partner Grace Lee, with associate Rasha Suleiman.